Patients with PANC and high PD-1+ counts and patients with BLAD and high FOXP3+ cell counts had, respectively, 64% and 68% reduced risk compared with those with intermediate counts (P = .03, Fig 4, Data Supplement, Table S5). The gene discussed is FOXP3; the disease is bladder adenocarcinoma.